Toramine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Toramine

Quick Facts

Property Description
Active Ingredient Ketorolac (as tromethamine salt)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin / Type Synthetic / Acetic Acid Derivative
General Purpose Short-term management of acute, moderate-to-severe pain
Forms Oral tablet, injection, nasal spray, ophthalmic solution

What is the General Class and Definition of Toramine?

Toramine is a highly potent, prescription-only medication primarily classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its active substance is Ketorolac (often utilized as Ketorolac tromethamine), which belongs specifically to the acetic acid derivative subgroup of NSAIDs. Toramine is clinically recognized for its ability to manage acute moderate-to-severe pain with an analgesic strength often described as comparable to certain opioid medications. This powerful, non-narcotic efficacy makes it a critical component for the short-term management of intense discomfort in adult patients.


Composition, Origin, and Available Preparations

The active component, Ketorolac, is a synthetic chemical compound that exists as a racemic mixture; however, its primary therapeutic effect is carried by the specific (S)-(-) enantiomer. Toramine is made available in several distinct pharmaceutical preparations, ensuring therapeutic flexibility across various clinical needs. This includes the high-potency parenteral solution for intramuscular (IM) or intravenous (IV) injection alongside the standard oral tablet. Furthermore, the availability of specialized forms, such as the nasal spray and ophthalmic solution, demonstrates the compound's versatility for multiple routes of administration addressing both systemic and localized acute pain scenarios.


What is the Primary Therapeutic Purpose of Toramine?

The primary therapeutic purpose of Toramine is to serve as a powerful analgesic and anti-inflammatory agent to quickly alleviate significant pain. The medicine works by directly acting as a potent inhibitor of prostaglandin synthesis, a fundamental biochemical process. By blocking the creation of these lipid compounds that signal and mediate pain and inflammation, Toramine reduces discomfort at its source. Its general function, therefore, is to provide swift, substantial pain relief that is non-habit-forming, fulfilling a crucial need when robust, temporary relief from acute, severe pain is required.

What side effects are possible with Toramine?

Safety and Adverse Reactions for Toramine

Toramine is associated with significant safety concerns and is indicated only for short-term use (maximum of five days) due to increased risk of serious adverse reactions with higher doses or prolonged treatment.


Serious and Clinically Significant Risks (Boxed Warnings)

Official regulatory documents emphasize two critical safety warnings:

  • Gastrointestinal Risk: Toramine can cause serious gastrointestinal (GI) adverse events, including ulceration, bleeding, and perforation of the stomach or intestines, which may be fatal. These events can occur without warning symptoms and are a particular concern for elderly patients.
  • Cardiovascular Thrombotic Events: Toramine may increase the risk of serious cardiovascular thrombotic events (including myocardial infarction and stroke), which can be fatal. This risk may increase with the duration of use and is also relevant to patients with pre-existing cardiovascular risk factors. The drug is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Safety Restrictions and Contraindications

Use of Toramine is contraindicated in several specific situations, including:

  • Patients with active peptic ulcer disease or a recent history of GI bleeding or perforation.
  • Patients with suspected or confirmed cerebrovascular bleeding or those at high risk of bleeding (due to its effect on platelet function).
  • Use during labor, delivery, or in pregnant women starting at 30 weeks gestation.
  • Patients with advanced renal impairment or severe heart failure.
  • Concomitant use with other non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.

Common Adverse Reactions

Commonly reported side effects (affecting ge1% of patients) often involve the gastrointestinal and nervous systems. These include, but are not limited to, headache, dizziness, drowsiness, nausea, indigestion (dyspepsia), diarrhea, and edema (swelling).

Overdose and Emergency Response

Overdose and When to Seek Help

The information below on Toramine (Ketorolac tromethamine) overdose is based strictly on the acute NSAID overdose management guidelines and specific documented findings found within government regulatory prescribing information.

Required Emergency Action

Individuals who suspect an overdose must seek medical attention immediately. Patients with clinically significant symptoms, especially following a large oral overdose, require close monitoring in a hospital setting.

Documented Overdose Manifestations

Symptoms following acute overdose are typically limited and reversible. Officially documented manifestations include:

  • Gastrointestinal Effects: Nausea, vomiting, epigastric pain, and abdominal pain.
  • CNS Effects: Lethargy and drowsiness.

Serious Outcomes and Treatment

While rare, serious outcomes documented in regulatory sources include acute renal failure, hypertension, respiratory depression, and coma. Management is strictly symptomatic and supportive, as no specific antidote for a Toramine overdose exists.

Feature Management Statement
Antidote No specific antidote is available.
Supportive Care Treatment relies on symptomatic and supportive care.
Ineffective Measures Hemodialysis, forced diuresis, and alkalization of urine may not be useful due to high protein binding.

For recent oral overdoses (within four hours), supportive procedures such as the administration of activated charcoal may be considered by healthcare providers.

Therapeutic Uses of Toramine

What Toramine Treats: Main Uses and Benefits

Toramine is a medication applied across domains where additional symptomatic support is needed for the short-term management of moderately severe acute pain. It is commonly used as a non-narcotic option to help ease patient discomfort. It is typically used to help relieve pain, often following surgery.


Key Therapeutic Focus

The primary therapeutic focus may involve managing symptom clusters that may become intense or disruptive, particularly those associated with recent medical procedures or conditions presenting with disruptive symptom manifestations tied to inflammatory or irritative states. It is considered relevant for managing symptoms that create noticeable physiological strain and may appear suddenly. Toramine is frequently applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate for short-duration episodes.

“It is commonly used to help with symptom clusters that appear suddenly or fluctuate.”

It contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability when symptoms interfere with routine activities. The medication is commonly used across conditions presenting with acute episodes like post-surgical discomfort and pain caused by acute inflammation.

Quick Fact: Support for Symptoms of Physical Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use This Medicine

Official regulatory documents define strict limitations on who is eligible to use this medicine. It is primarily approved for short-term use in adult patients.

Populations for Whom Use is CONTRAINDICATED (Must Not Use)

Use of this medicine is strictly CONTRAINDICATED (prohibited) in patients with the following conditions or circumstances, as established in official labeling:

  • Gastrointestinal (GI) Issues: Any patient with active peptic ulcer disease or a recent history of GI bleeding or perforation.
  • Kidney Function: Patients with advanced renal impairment or those at risk for kidney failure due to volume depletion.
  • Bleeding Risk: Individuals with a high risk of bleeding, such as those with suspected cerebrovascular bleeding or hemorrhagic disorders.
  • Hypersensitivity: Those with a known allergic reaction to the drug itself or to aspirin/other NSAIDs.
  • Procedural Use: Patients undergoing Coronary Artery Bypass Graft (CABG) surgery or those in labor and delivery.

Age and Pregnancy Restrictions

Use in pediatric patients is generally not indicated. The medicine is contraindicated for use in nursing mothers and for use during labor and delivery. Special consideration and dosage adjustments are required for older patients (typically 65 years).

What should I know about interactions with other medicines?

Toramine Interactions with Other Medicines and Products

Official regulatory information requires strict adherence to documented interaction constraints for Toramine (Ketorolac tromethamine).

Formally Contraindicated Combinations

Co-administration with the following substances is prohibited due to the risk of significant adverse effects or increased drug levels:

  • Aspirin and Other NSAIDs: Increases the cumulative risk of serious gastrointestinal complications.
  • Probenecid: Prohibited because it significantly reduces Toramine's renal clearance, leading to dangerously high plasma levels.
  • Lithium Salts: Contraindicated due to the risk of decreased lithium clearance and subsequent toxicity.
  • Pentoxifylline and high-dose Methotrexate (or ge 15 mg/week): Prohibited due to heightened bleeding risk or increased toxicity, respectively.

Pharmacodynamic and Clearance Considerations

Toramine interacts with several drug classes by inhibiting platelet function and renal prostaglandin synthesis. The co-administration of Anticoagulants (e.g., Warfarin) or SSRIs/SNRIs significantly increases the risk of bleeding. Toramine may also diminish the blood pressure and water-losing effects of Diuretics and ACE Inhibitors/ARBs, potentially increasing the risk of renal impairment.

Other Constraints

  • Cumulative Duration: The total combined treatment time using all forms of Toramine (oral, injection, nasal) must not exceed 5 days.
  • Alcohol: Official warnings indicate that co-ingestion with alcohol may worsen side effects.
  • Population Note: Elderly patients and those with existing renal impairment are at a heightened risk for severe interaction consequences.

Mechanism of Action

Toramine (Ketorolac) operates through a pharmacodynamic mechanism that inhibits the synthesis of prostaglandins and other inflammatory lipid mediators.

Molecular Target: Non-Selective Cyclooxygenase (COX) Inhibition

This core mechanism involves the drug acting as a competitive inhibitor of both the Cyclooxygenase-1 (COX-1) and COX-2 enzymes. By blocking the active site, the drug prevents the conversion of arachidonic acid into prostaglandins, which are central components of nociceptive and inflammatory signaling pathways. This non-selective blockade of prostaglandin synthesis is the fundamental action that shapes the drug's physiological profile.

Dual Action: Modulation of Peripheral and Central Nociceptive Signaling

The mechanism modulates the transmission of nociceptive signals at two critical points: peripherally and centrally. Reducing prostaglandin synthesis prevents the sensitization of nociceptors (peripheral pain receptors). Simultaneously, the drug modulates the central nervous system by inhibiting COX activity in the spinal cord and brain, which dampens the amplification of pain signals (central sensitization). This dual-level interference results in simultaneous modulation of both peripheral receptor sensitization and central signal amplification.

Mechanistic Constraint: Inherent Consequence of Non-Selectivity

A consequence of the non-selective mechanism is the concurrent influence on the constitutive COX-1 enzyme, which maintains homeostatic functions. This modulation extends to systems regulating renal blood flow and ensuring gastric mucosal lining integrity, highlighting the inherent consequence of non-selectivity associated with this class of enzyme inhibition.

Dosage and Administration Information

How to Use Toramine

Toramine (Ketorolac tromethamine) is administered using a structured, sequential protocol that strictly limits the total duration of use. The medication is officially indicated for short-term management and is not to be used for chronic pain.


Administration Route and Duration

Treatment must always begin with the parenteral formulation via Intravenous (IV) or Intramuscular (IM) injection. The oral tablet is used only for continuation therapy as a step-down from the injectable form. The combined total duration of both IV/IM and oral administration must not exceed five days in adults.


Standard Dosing and Frequency

Administration follows a scheduled pattern, with doses typically given every four to six hours.

Usage Phase Standard Adult Dose (Typically ge 50 kg) Maximum Daily Dose (Total)
IV/IM Injection 30 mg every 6 hours 120 mg
Oral Continuation 10 mg every 4 to 6 hours (after 20 mg initial dose) 40 mg (Oral)

Procedural and Population Constraints

Specific procedural requirements must be followed during administration. The IV bolus, for instance, must be administered over no less than 15 seconds. Furthermore, mandatory dose adjustments are required for certain populations. For older adults (aged 65 years and over) or patients with low body weight (under 50 kg), the total maximum daily dose for IV/IM use is strictly reduced to 60 mg. This ensures the medicine is used within the established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Toramine


Evidence for Use in Acute Pain Management

Research was studied for use in adult patients experiencing acute moderate-to-severe pain, including pain following surgical procedures. The evidence base includes Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluated Toramine against placebo or active control agents. These studies were used in research exploring how symptoms change over time. Outcomes frequently monitored included the change in patient-reported outcomes describing perceived discomfort and the time interval required to reach a specific level of symptom change.

In post-surgical settings, studies monitored the total opioid consumption in the immediate recovery period. Findings describe patterns observed in the studies related to the amount of opioid painkiller required by patients over the first 24 hours of recovery.


Evidence for Use in Acute Migraine and Select Colicky Pain

Toramine was evaluated in settings involving conditions characterized by fluctuating or episodic manifestations, such as acute migraine headaches. Studies monitored outcomes describing episodic or acute changes, specifically focusing on the time to achieve headache freedom and the stability of the relief. Research explored the relative findings of Toramine compared to various other medications. The evidence for these specific acute scenarios is limited compared to the postoperative setting, and comparative evidence is lacking for some of the newer formulations.


Limitations and Evidence Gaps

The available clinical evidence is concentrated on short-term symptom patterns because the use of systemic Toramine is strictly limited to a maximum of five days. Consequently, long-term effects are not fully established. Data for certain groups remain insufficient, particularly for optimizing therapeutic approaches in pediatric patients, and the results apply only to the populations studied. Research provides context but not individual predictions.

Key Studies & References

  1. Ketorolac drug information

Frequently Asked Questions (FAQ)

Common questions about Toramine (FAQ)

Q: How quickly does Toramine start to work after taking it?

Official clinical information states that for the injection form (IV or IM), the pain relief effect usually begins within 30 minutes. The medication is generally expected to reach its most noticeable effect about 1 to 2 hours following administration.


Q: Can Toramine be stopped suddenly after long-term use?

Toramine is strictly indicated and limited for short-term use only, with the total time not exceeding five days. This is mandated by regulatory agencies to help reduce the risk of serious adverse events that increase with longer use. Therefore, the medicine is not intended for long-term use.


Q: Is it common to feel tired while taking Toramine?

Official safety data lists adverse events affecting the nervous system, including drowsiness (somnolence) and dizziness. Fatigue or tiredness is also noted in some post-marketing experience and is listed as a potential adverse reaction in regulatory documents.


Q: Does Toramine affect sleep or cause insomnia?

Yes, official regulatory labeling includes insomnia (difficulty sleeping) as one of the reported nervous system adverse reactions. Patients should follow the instructions provided by their healthcare professional regarding side effects.


Q: How does Toramine interact with alcohol?

Regulatory warnings specifically advise caution regarding the co-ingestion of Toramine and alcohol. Using the medicine with alcohol may increase the risk of serious gastrointestinal complications, such as irritation and bleeding.


Q: What are some of the less common but known side effects of Toramine?

Adverse reactions with an incidence of less than 1% are documented in official safety information. These include certain nervous system effects and skin reactions, as listed in the full adverse reactions section of the product labeling.


Q: Can Toramine be taken on an empty stomach?

Toramine is associated with a risk of serious gastrointestinal issues, such as ulcers and bleeding. Although specific food instructions vary, patients should follow the administration instructions provided by their healthcare professional.


Q: Is Toramine a controlled substance?

No, Toramine (Ketorolac tromethamine) is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not classified as a narcotic or a controlled substance by the U.S. Drug Enforcement Administration (DEA) or the FDA.


Q: Why is Toramine sometimes called by a different name?

The active substance in the medicine is Ketorolac tromethamine. This ingredient is sometimes referred to by various brand names (e.g., Toradol, Sprix) that are used in different formulations or regions. All of these names refer to the same active medication.


Q: Is Toramine the same kind of medicine as [similar-sounding drug name]?

Toramine belongs to the pharmacological class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Any similarity to another medication would depend entirely on whether that other drug is also classified within the NSAID group or shares the same active ingredient.


Q: Can Toramine cause weight changes?

Official safety data does not specifically cite general weight gain or loss as a common side effect. However, the product information does list edema (swelling due to fluid retention) as a commonly reported adverse reaction, which can result in noticeable weight fluctuations.


Q: Can Toramine affect fertility or conception?

Similar to other medications that work by inhibiting prostaglandin synthesis, Toramine may potentially adversely affect female fertility. The medicine is generally used with caution in women who are trying to conceive, as described in official labeling.


Q: Is there a generic version of Toramine?

Yes, the active ingredient in Toramine, known as Ketorolac tromethamine, is widely available in generic formulations that are approved by regulatory bodies.


Q: Does Toramine need to be taken at a specific time of day?

Official dosing guidelines specify that the medicine should be administered at regular intervals, such as every four to six hours, as needed. The emphasis is on the consistent frequency of the dose rather than taking it at a specific time like morning or evening.


Q: Is it possible to develop a tolerance to Toramine?

Toramine is a non-narcotic pain reliever and is officially described as not habit-forming. It is not associated with the typical patterns of physical or mental dependence or the development of tolerance seen with certain other pain medications.


Q: How does the body eliminate Toramine?

The process by which the body removes the active substance is primarily through renal excretion. This means that the drug and its breakdown products are eliminated from the body by the kidneys.


Q: Is Toramine addictive or habit-forming?

No. Toramine is an NSAID and is officially described in regulatory documents as not being habit-forming. It does not possess the addictive properties associated with narcotic or opioid analgesics.


Q: Why would a doctor choose Toramine over other treatment options?

Toramine is officially indicated for the short-term management of moderately severe acute pain. It is often utilized when pain relief at an intense analgesic level is required, offering a non-narcotic option for temporary, significant pain.


Q: Are there any known interactions with herbal supplements and Toramine?

While regulatory documents typically focus on drug-to-drug interactions, general safety warnings for this class of drug advise caution. This is particularly relevant with supplements that may impact platelet aggregation (the body's ability to clot blood) or kidney function.


Q: Does the effectiveness of Toramine change over time?

Because the use of Toramine is strictly limited to a maximum of five days, there is no established regulatory information regarding any change in effectiveness (such as tolerance or loss of effect) over longer treatment periods.


Q: Is Toramine considered a long-term treatment or short-term?

Toramine is officially classified and strictly indicated for short-term management of acute pain only. Regulatory guidelines mandate that the total combined duration of use must not exceed five days.


Q: Why do some people report feeling better right away, and others don't?

Variability in how quickly the drug takes effect can be attributed to differences in how each person's body processes the medicine. Factors like body weight, age, and individual metabolic rates influence the time required to reach the maximum effective drug concentration in the bloodstream.


Q: Does Toramine carry a risk of allergic reactions?

Yes. Official product information states that the medicine is contraindicated (must not be used) in anyone with a known allergic reaction or hypersensitivity to Toramine itself, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID).


Q: Can teenagers or children use Toramine?

Toramine is generally indicated for use in adult patients aged 16 years and older. The injection form is typically not indicated for use in pediatric patients, and age restrictions are defined in official labeling.


Q: What is the meaning of the letter or number after the drug name 'Toramine'?

Letters or numbers are often used by manufacturers and regulatory bodies to distinguish between different characteristics of the medicine. This usually indicates the strength (e.g., 10 mg or 30 mg) or the specific formulation (e.g., a tablet versus an injection).


Q: Are there specific tests needed before starting Toramine?

Regulatory warnings indicate that patients with conditions like pre-existing kidney problems or risk of bleeding need careful evaluation. Therefore, assessment and close monitoring of functions such as kidney health are required before and during administration.


Q: What is the official safety classification of Toramine for use?

Official labeling provides specific safety classifications for different populations. For instance, the drug is classified as Contraindicated for use in pregnancy beginning at 30 weeks gestation due to the potential risk to the fetal cardiovascular system.

How should Toramine be stored and disposed of?

How to Store and Dispose of Toramine (Ketorolac Tromethamine Tablets)

Toramine tablets must be stored according to official regulatory requirements to maintain product integrity and safety. The mandated storage condition is Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C.

Storage Requirement Rule
Environmental Protection Protect from light, excessive humidity, and heat. Do not refrigerate or freeze.
Container Rule Keep in a tight, light-resistant container with a child-resistant closure.
Child Safety Keep this and all medications out of the sight and reach of children.

Disposal

Unused or expired Toramine should be disposed of safely. The FDA advises utilizing drug take-back programs when available. If a take-back program is not accessible, the medicine should be mixed with an unappealing substance (such as dirt) and placed into a sealed container before disposal in household trash. Do not flush the tablets down a toilet or pour them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Toramine found in:

A-Z Index: